Pregled bibliografske jedinice broj: 2259
Analysis of telomere length in chronic myelogenous leukemia
Analysis of telomere length in chronic myelogenous leukemia // Blood / Apelbaum, D. (ur.).
Washington (MD): ASH, 1997. str. 195a-195a (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 2259 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Analysis of telomere length in chronic myelogenous leukemia
Autori
Boultwood, Jackie ; Fidler, Carrie ; Watkins, Fiona ; Snowball, Jo ; Haynes, Steven ; Kušec, Rajko ; Shepherd, Paul ; Gaiger, Alex ; Littlewood, Tim ; Wainscoat, James
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Blood
/ Apelbaum, D. - Washington (MD) : ASH, 1997, 195a-195a
Skup
Annual Meeting of American Society of Hematology
Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 05.12.1997. - 09.12.1997
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
telomere; chronic myelogenous leukaemia; blasgic crisis
Sažetak
The aim of this study was to determine whether a reduction in telomere length is associated with disease progression in chronic myelogenous leukemia (CML). We have studied telomere length in the peripheral blood leukocyte samples of a large group of patients with CML by Southern blot hybridization using the (TTAGGG)4 probe. Serial measurements on a subset of patients were performed. The average telomere length expressed as the peak telomere repeat array (TRA) in the peripheral blood samples obtained from a group of 20 healthy age-matched controls (2169 years old, mean age 45) ranged between 7.6 and 11.5 kb (mean peak TRA 9.2 kb). 44 patients in the chronic phase of CML were studied; 31/44 (70%) showed telomere reduction (<7.6 kb) relative to age-matched controls and the mean peak TRA was 6.4 kb (range 4.010.6 kb). Serial samples were analysed from 12 patients at both chronic phase (CP) and accelerated phase (AC) and/or blast crisis (BC). 12/12 (100%) in accelerated phase and/or blast crisis showed telomere reduction relative to age matched controls and the mean peak TRA was 4.1 kb (range 3.05.4 kb). These data demonstrate that there is a marked reduction in the mean peak TRA in accelerated or blast phase CML as compared to chronic phase. Case number123456789101112CP6.44.05.64.57.06.37.55.94.85.54.17.1AC/BC3.13.24.83.05.24.75.44.43.93.33.65.0 In the serial study we found that the peak TRA in the accelerated or blast phase was reduced compared to the corresponding paired sample in the chronic phase in all cases studied (see table). These data show that a marked reduction in telomere length is associated with disease progression in CML; this phenomenon may represent a valuable marker for monitoring disease evolution.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb
Profili:
Rajko Kušec
(autor)